GlassScriptPhysician profile
Noemi D Cabrera
NPI 1558872986
$7,873.70
in general payments reported to CMS, 2019-2025
34 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,194 · 2022: $3,361 · 2023: $2,466 · 2024: $476 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,318.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,346.81 | 2021-2025 | |
| Novo Nordisk INC | $896.32 | 2021-2024 | Rybelsus, Ozempic, Tresiba |
| Astellas Pharma US INC | $840.68 | 2021-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $693.21 | 2021-2023 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $583.06 | 2021-2023 | Jardiance, Synjardy |
| Nestle Healthcare Nutrition INC. | $390.65 | 2022-2023 | |
| Lilly USA, LLC | $301.01 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Hologic Sales and Service, LLC | $296.95 | 2023 | Aptima |
| Ironwood Pharmaceuticals, INC | $251.95 | 2021-2023 | Linzess |
| Merck Sharp & Dohme LLC | $250.40 | 2021-2023 | Verquvo, Januvia, Belsomra |
| Abbott Laboratories | $159.88 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $134.51 | 2021-2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.37 | 2022-2023 | Xifaxan |
| Esperion Therapeutics, INC. | $78.87 | 2023 | Nexlizet, Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $59.96 | 2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $48.03 | 2023-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $44.66 | 2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $41.78 | 2023 | Eliquis |
| Dexcom, INC. | $31.70 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $28.35 | 2021-2023 | |
| Gilead Sciences, INC. | $24.50 | 2023 | |
| Lifescan, INC. | $23.82 | 2022 | |
| Sumitomo Pharma America, INC. | $21.27 | 2023 | Gemtesa |
| Redhill Biopharma INC. | $20.67 | 2022 | |
| Coopersurgical, INC. | $17.91 | 2021 | |
| Scilex Pharmaceuticals INC. | $17.75 | 2022 | |
| Impel Pharmaceuticals INC. | $17.47 | 2023 | Trudhesa |
| Novartis Pharmaceuticals Corporation | $17.16 | 2022 | |
| Pfizer INC. | $17.13 | 2023 | |
| Almatica Pharma LLC | $17.11 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.69 | 2022 | |
| Mannkind Corporation | $16.46 | 2023 | Afrezza |
| Lundbeck LLC | $16.39 | 2023 | Rexulti |
| Boston Scientific Corporation | $16.22 | 2025 | General - Pain Management |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noemi Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.